Valuation: Annexon, Inc.

Market Cap 69Cr 61Cr 57Cr 52Cr 98Cr 6.61TCr 98Cr 684.37Cr 265.07Cr 3.38TCr 259.09Cr 253.49Cr 11TCr P/E 2026 *
-3.51x
P/E 2027 * -3.72x
Enterprise Value 60Cr 53Cr 50Cr 45Cr 85Cr 5.75TCr 85Cr 594.57Cr 230.29Cr 2.94TCr 225.1Cr 220.23Cr 9.43TCr EV / Sales 2026 *
-
EV / Sales 2027 * 15.7x
Free-Float
94.44%
Yield 2026 *
-
Yield 2027 * -
1 day-4.21%
1 week-13.95%
Current month-26.32%
1 month-29.32%
3 months-29.32%
6 months-32.15%
Current year-27.49%
1 week 3.63
Extreme 3.63
4.36
1 month 3.63
Extreme 3.63
5.32
Current year 3.63
Extreme 3.63
7.18
1 year 2.54
Extreme 2.54
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
22.49
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 01/12/2014
Director of Finance/CFO 53 01/06/2019
Chief Tech/Sci/R&D Officer 68 27/07/2023
Director TitleAgeSince
Director/Board Member 58 01/12/2014
Director/Board Member 67 05/02/2021
Director/Board Member 56 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Free

Director

1,75,000 0.0923%
28/05/26
Alerce Investment Management LP
BuyCompany 6,13,497 0.3775%
11/05/26 Buy

Director

8,000 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
-4.21%-13.95%+30.47%+46.18% 69Cr
-3.30%+1.50%+51.24%+99.26% 7.23TCr
+1.25%-3.01%+40.12%+77.12% 6.02TCr
+2.12%+5.26%+32.50%+21.28% 2.77TCr
-3.06%-1.81%-13.10%+357.06% 2.57TCr
-0.75%+2.56%+0.45%-4.46% 2.47TCr
+0.40%+0.75%+22.91%-9.68% 2.07TCr
-1.70%-2.12%+146.86%+314.52% 1.51TCr
+0.36%-0.34%+50.32%+166.42% 1.44TCr
+0.21%+1.17%-8.07%+499.10% 1.42TCr
Average -0.87%-1.00%+35.37%+156.68% 2.76TCr
Weighted average by Cap. -0.77%+0.27%+36.30%+128.91%

Financials

2026 *2027 *
Net sales - 3.89Cr 3.41Cr 3.23Cr 2.94Cr 5.5Cr 373Cr 5.54Cr 39Cr 15Cr 190.56Cr 15Cr 14Cr 612.43Cr
Net income -21Cr -19Cr -18Cr -16Cr -30Cr -2.03TCr -30Cr -209.89Cr -81Cr -1.04TCr -79Cr -78Cr -3.33TCr -21Cr -18Cr -17Cr -16Cr -30Cr -2.01TCr -30Cr -207.61Cr -80Cr -1.03TCr -79Cr -77Cr -3.29TCr
Net Debt -9.05Cr -7.95Cr -7.5Cr -6.84Cr -13Cr -867.86Cr -13Cr -90Cr -35Cr -443.37Cr -34Cr -33Cr -1.42TCr -8.07Cr -7.08Cr -6.69Cr -6.1Cr -11Cr -773.53Cr -11Cr -80Cr -31Cr -395.18Cr -30Cr -30Cr -1.27TCr
Logo Annexon, Inc.
Annexon, Inc. is a biopharmaceutical company advancing targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Tanruprubart is an investigational-targeted immunotherapy delivered in a single infusion to rapidly halt aggressive neuroinflammation and damage in GBS, an acute, rare, neuromuscular emergency. The Vonaprument is an investigational neuroprotective inhibitor of C1q and the classical complement cascade delivered intravitreally for dry AMD with GA, a leading cause of blindness. ANX1502, a novel oral small molecule for autoimmune conditions. The Company's next wave programs include ANX005 and ANX009. ANX009, a C1q-blocking Fab formulated for subcutaneous delivery, for patients with lupus nephritis.
Employees
92
Date Price Change Volume
25/26/25 $3.640 -4.21% 35,11,268
24/26/24 $3.800 -1.81% 20,22,863
23/26/23 $3.870 -7.42% 24,23,554
22/26/22 $4.180 -0.95% 20,00,238
21/26/21 $4.220 -0.24% 41,87,459
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.640USD
Average target price
15.29USD
Spread / Average Target
+319.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock